547 related articles for article (PubMed ID: 9149205)
1. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease.
Sandborn WJ
Am J Gastroenterol; 1997 May; 92(5):876-9. PubMed ID: 9149205
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine.
Egan LJ; Sandborn WJ; Tremaine WJ
Am J Gastroenterol; 1998 Mar; 93(3):442-8. PubMed ID: 9517654
[TBL] [Abstract][Full Text] [Related]
3. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506).
Fellermann K; Ludwig D; Stahl M; David-Walek T; Stange EF
Am J Gastroenterol; 1998 Oct; 93(10):1860-6. PubMed ID: 9772045
[TBL] [Abstract][Full Text] [Related]
4. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus for Crohn's disease.
Ruddock B
Issues Emerg Health Technol; 2006 Sep; (88):1-4. PubMed ID: 16981314
[TBL] [Abstract][Full Text] [Related]
6. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up.
Baumgart DC; Pintoffl JP; Sturm A; Wiedenmann B; Dignass AU
Am J Gastroenterol; 2006 May; 101(5):1048-56. PubMed ID: 16573777
[TBL] [Abstract][Full Text] [Related]
7. Clinical response does not correlate with intestinal or blood cyclosporine concentrations in patients with Crohn's disease treated with high-dose oral cyclosporine.
Sandborn WJ; Tremaine WJ; Lawson GM
Am J Gastroenterol; 1996 Jan; 91(1):37-43. PubMed ID: 8561141
[TBL] [Abstract][Full Text] [Related]
8. Review article: Medical therapy for fistulizing Crohn's disease.
Bressler B; Sands BE
Aliment Pharmacol Ther; 2006 Nov; 24(9):1283-93. PubMed ID: 17059510
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporin treatment of anal and perianal lesions associated with Crohn's disease.
Cat H; Sophani I; Lemann M; Modiglani R; Solue JC
Turk J Gastroenterol; 2003 Jun; 14(2):121-7. PubMed ID: 14614639
[TBL] [Abstract][Full Text] [Related]
10. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A.
Hanauer SB; Smith MB
Am J Gastroenterol; 1993 May; 88(5):646-9. PubMed ID: 8480725
[TBL] [Abstract][Full Text] [Related]
11. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease.
Ochsenkühn T; Göke B; Sackmann M
Am J Gastroenterol; 2002 Aug; 97(8):2022-5. PubMed ID: 12190171
[TBL] [Abstract][Full Text] [Related]
12. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.
Colombel JF; Loftus EV; Tremaine WJ; Pemberton JH; Wolff BG; Young-Fadok T; Harmsen WS; Schleck CD; Sandborn WJ
Am J Gastroenterol; 2004 May; 99(5):878-83. PubMed ID: 15128354
[TBL] [Abstract][Full Text] [Related]
13. Oral tacrolimus treatment of severe colitis in children.
Bousvaros A; Kirschner BS; Werlin SL; Parker-Hartigan L; Daum F; Freeman KB; Balint JP; Day AS; Griffiths AM; Zurakowski D; Ferry GD; Leichtner AM
J Pediatr; 2000 Dec; 137(6):794-9. PubMed ID: 11113835
[TBL] [Abstract][Full Text] [Related]
14. Refractory enterovesical and duodenocolic fistulas in Crohn's disease successfully managed with tacrolimus.
Fukuda A; Nakase H; Seno H; Nabeshima M; Sawada M; Chiba T
J Gastroenterol; 2005 Apr; 40(4):433-5. PubMed ID: 15870981
[No Abstract] [Full Text] [Related]
15. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae.
Lowry PW; Weaver AL; Tremaine WJ; Sandborn WJ
Inflamm Bowel Dis; 1999 Nov; 5(4):239-45. PubMed ID: 10579116
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
[TBL] [Abstract][Full Text] [Related]
17. [Optimizing treatment of complicated forms of inflammatory bowel disease. Fistulizing Crohn's disease].
Peñate M; Cruz-Santamaría M; Mendoza JL; Peña AS; Díaz-Rubio M; García-Paredes J
An Med Interna; 2003 Jan; 20(1):37-45. PubMed ID: 12666309
[No Abstract] [Full Text] [Related]
18. Recombinant human granulocyte-macrophage colony stimulating factor (sargramostim) as an alternative therapy for fistulizing Crohn's disease.
Magno P; Jiménez CE; Ortiz Z; Torres EA
P R Health Sci J; 2010 Mar; 29(1):60-5. PubMed ID: 20222336
[TBL] [Abstract][Full Text] [Related]
19. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
Gao Q; Hogezand RA; Lamers CB; Verspaget HW
Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
[TBL] [Abstract][Full Text] [Related]
20. MR of the small bowel with a biphasic oral contrast agent (polyethylene glycol): technical aspects and findings in patients affected by Crohn's disease.
Laghi A; Paolantonio P; Iafrate F; Borrelli O; Dito L; Tomei E; Cucchiara S; Passariello R
Radiol Med; 2003; 106(1-2):18-27. PubMed ID: 12951547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
